Skip to main content

Table 1 Baseline characteristics of studied patients

From: Differential leukocyte counts and cardiovascular mortality in very old patients with acute myocardial infarction: a Chinese cohort study

Variables

Overall (n = 523)

Deceased (n = 153)

Survived (n = 370)

p value

Clinical characteristics

Age, years

82.75 ± 2.74

83.32 ± 3.11

82.55 ± 2.55

0.006

Male, n (%)

329(60)

109(62)

220(59)

0.576

BMI, kg/m2

23.77 ± 3.50

23.28 ± 3.84

23.96 ± 3.34

0.078

Smoking, n (%)

215(40)

71 (43)

141 (39)

0.445

Family history of CAD, n (%)

55(10)

22 (13)

33 (9)

0.307

Hypertension, n (%)

409(75)

134(76)

275 (74)

0.671

Diabetes mellitus, n (%)

221(41)

85 (49)

136(37)

0.005

MI type

STEMI

244(47)

64(42)

180(49)

0.211

NSTEMI

279(53)

89(58)

190(51)

 

Laboratory test

Triglyceride, mmol/L

1.22 (0.93–1.56)

1.21 (0.92–1.59)

1.23 (0.93–1.52)

0.887

TC, mmol/L

3.81 ± 0.94

3.78 ± 0.93

3.82 ± 0.94

0.623

HDL-C, mmol/L

1.09 ± 0.29

1.05 ± 0.29

1.11 ± 0.29

0.052

LDL-C, mmol/L

2.24 ± 0.78

2.20 ± 0.78

2.26 ± 0.77

0.356

Lipoprotein(a), mg/L

203.69 (95.98–438.00)

220.44 (101.04–409.51)

202.00 (93.92–460.02)

0.552

Creatinine, μmol/L

106.86 ± 40.54

122.56 ± 50.36

100.38 ± 33.71

< 0.001

hsCRP, mg/L

4.88 (1.84–11.28)

8.29 (3.06–12.20)

4.19 (1.56–10.68)

< 0.001

LVEF (%)

52.73 ± 10.73

49.47 ± 11.86

54.29 ± 9.79

< 0.001

CK-MB, ng/mL

27.65 ± 58.10

30.94 ± 62.07

26.26 ± 56.37

0.421

Troponin I, ng/mL

4.86 ± 8.64

3.73 ± 6.65

7.58 ± 11.73

< 0.001

Leukocyte parameters

Leukocytes, 109/L

7.42 ± 2.81

8.21 ± 4.43

7.13 ± 2.41

< 0.001

Neutrophils, 109/L

5.28 ± 2.67

6.09 ± 3.58

4.91 ± 2.09

< 0.001

Lymphocytes, 109/L

1.46 ± 0.60

1.28 ± 0.57

1.53 ± 0.61

< 0.001

Monocytes, 109/L

0.48 ± 0.20

0.52 ± 0.22

0.47 ± 0.18

0.013

Eosinophils, 109/L

0.15 ± 0.17

0.12 ± 0.14

0.16 ± 0.19

0.008

Basophils, 109/L

0.02 ± 0.02

0.02 ± 0.02

0.02 ± 0.03

< 0.001

Neutrophil-to-lymphocyte ratio

4.58 ± 4.57

6.21 ± 6.72

3.83 ± 2.86

< 0.001

Monocyte-to-lymphocyte ratio

0.38 ± 0.22

0.48 ± 0.30

0.34 ± 0.17

< 0.001

NMLR

4.96 ± 4.73

7.15 ± 7.13

4.17 ± 2.96

< 0.001

Eosinophil-to-leukocyte ratio

0.02 ± 0.03

0.02 ± 0.02

0.02 ± 0.03

0.005

Treatment at admission

Aspirin, n (%)

504(96.2)

147 (95.5)

357(96.5)

0.618

Statin, n (%)

486(92.7)

137(89.0)

349 (94.3)

0.041

Beta-blocker, n (%)

479(91.4)

136(88.3)

343(92.7)

0.102

CCB, n (%)

114(21.8)

30(19.5)

84(22.7)

0.486

ACE-I/ARB, n (%)

279(53.3)

69 (45.1)

210(56.8)

0.016

Clopidogrel, n (%)

486(92.7)

142 (92.2)

344(93.0)

0.716

Ticagrelor, n (%)

32(6.3)

10(6.5)

22(5.9)

0.842

CABG

5(1.0)

1(0.6)

4(1.1)

1.000

PCI

228(43.5)

38(24.7)

190(51.4)

< 0.001

  1. Data were expressed as mean ± SD, median (Q1–Q3 quartiles) or n (%)
  2. BMI body mass index, CAD coronary artery disease, MI myocardial infarction, STEMI ST-segment elevation myocardial infarction, NSTEMI Non-ST-segment elevation myocardial infarction, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, hsCRP high sensitivity C-reactive protein, LVEF left ventricular ejection fraction, NMLR neutrophil-plus-monocyte-to-lymphocyte ratio, CCB calcium channel blockers, ACE-I angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, SD standard deviation
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us